1. Home
  2. IMNM vs SPNT Comparison

IMNM vs SPNT Comparison

Compare IMNM & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$17.97

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo SiriusPoint Ltd.

SPNT

SiriusPoint Ltd.

HOLD

Current Price

$25.71

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
SPNT
Founded
2006
2011
Country
United States
Bermuda
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
IMNM
SPNT
Price
$17.97
$25.71
Analyst Decision
Strong Buy
Buy
Analyst Count
17
5
Target Price
★ $35.19
$28.75
AVG Volume (30 Days)
★ 1.4M
707.5K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
★ 250.00
EPS
N/A
★ 1.40
Revenue
$6,941,000.00
★ $3,205,100,000.00
Revenue This Year
N/A
$3.57
Revenue Next Year
$18,803.97
$5.58
P/E Ratio
★ N/A
$18.46
Revenue Growth
N/A
★ 23.09
52 Week Low
$14.64
$17.71
52 Week High
$30.06
$26.50

Technical Indicators

Market Signals
Indicator
IMNM
SPNT
Relative Strength Index (RSI) 35.71 60.25
Support Level $17.83 $22.22
Resistance Level $23.48 $26.30
Average True Range (ATR) 0.98 0.60
MACD 0.14 0.07
Stochastic Oscillator 32.67 76.04

Price Performance

Historical Comparison
IMNM
SPNT

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About SPNT SiriusPoint Ltd.

SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.

Share on Social Networks: